|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-8-28
|
|
pubmed:abstractText |
Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
87-93
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7623074-Adrenal Cortex Hormones,
pubmed-meshheading:7623074-Adult,
pubmed-meshheading:7623074-Aged,
pubmed-meshheading:7623074-Antineoplastic Agents,
pubmed-meshheading:7623074-Astrocytoma,
pubmed-meshheading:7623074-Brain Neoplasms,
pubmed-meshheading:7623074-Combined Modality Therapy,
pubmed-meshheading:7623074-Female,
pubmed-meshheading:7623074-Glioma,
pubmed-meshheading:7623074-Humans,
pubmed-meshheading:7623074-Imides,
pubmed-meshheading:7623074-Isoquinolines,
pubmed-meshheading:7623074-Male,
pubmed-meshheading:7623074-Middle Aged,
pubmed-meshheading:7623074-Naphthalimides,
pubmed-meshheading:7623074-Nervous System Diseases,
pubmed-meshheading:7623074-Oligodendroglioma,
pubmed-meshheading:7623074-Recurrence,
pubmed-meshheading:7623074-Tomography, X-Ray Computed,
pubmed-meshheading:7623074-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Phase II study of amonafide in patients with recurrent glioma.
|
|
pubmed:affiliation |
St. Luke's Hospitals CCOP, Fargo, ND 58123, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
